Literature DB >> 19084399

Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease.

N A M E Van der Beek1, M L C Hagemans, A J J Reuser, W C J Hop, A T Van der Ploeg, P A Van Doorn, J H J Wokke.   

Abstract

To determine the rate of disease progression in patients with late-onset Pompe disease, we collected longitudinal data on pulmonary function and skeletal muscle strength in 16 patients whose symptoms had started in childhood or adulthood. The mean duration of follow-up was 16 years (range 4-29 years). During the follow-up period, eight patients (50%) became wheelchair bound and three (19%) became ventilator dependent. At a group level, pulmonary function deteriorated by 1.6% per year, and proximal muscle weakness progressed gradually. At the individual level, however, the rate and extent of progression varied highly between patients. In two thirds of patients, pulmonary function and muscle strength declined simultaneously and to the same extent. The remaining one third of patients showed a variable, sometimes rapidly progressive course, leading to early respirator or wheelchair dependency. These individual differences, especially in pulmonary dysfunction, indicate the need for regular monitoring every 6-12 months depending on the rate of disease progression.

Entities:  

Mesh:

Year:  2008        PMID: 19084399     DOI: 10.1016/j.nmd.2008.11.007

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  42 in total

1.  36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy.

Authors:  Caroline Regnery; Cornelia Kornblum; Frank Hanisch; Stefan Vielhaber; Nicola Strigl-Pill; Birgit Grunert; Wolfgang Müller-Felber; Franz Xaver Glocker; Matthias Spranger; Marcus Deschauer; Eugen Mengel; Benedikt Schoser
Journal:  J Inherit Metab Dis       Date:  2012-01-31       Impact factor: 4.982

2.  Urge incontinence and gastrointestinal symptoms in adult patients with pompe disease: a cross-sectional survey.

Authors:  Nesrin Karabul; Anika Skudlarek; Janine Berndt; Cornelia Kornblum; Rudolf A Kley; Stephan Wenninger; Nikolaus Tiling; Eugen Mengel; Ursula Plöckinger; Matthias Vorgerd; Marcus Deschauer; Benedikt Schoser; Frank Hanisch
Journal:  JIMD Rep       Date:  2014-08-26

3.  Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial.

Authors:  S Strothotte; N Strigl-Pill; B Grunert; C Kornblum; K Eger; C Wessig; M Deschauer; F Breunig; F X Glocker; S Vielhaber; A Brejova; M Hilz; K Reiners; W Müller-Felber; E Mengel; M Spranger; Benedikt Schoser
Journal:  J Neurol       Date:  2009-08-01       Impact factor: 4.849

Review 4.  Pompe disease gene therapy.

Authors:  Barry J Byrne; Darin J Falk; Christina A Pacak; Sushrusha Nayak; Roland W Herzog; Melissa E Elder; Shelley W Collins; Thomas J Conlon; Nathalie Clement; Brian D Cleaver; Denise A Cloutier; Stacy L Porvasnik; Saleem Islam; Mai K Elmallah; Anatole Martin; Barbara K Smith; David D Fuller; Lee Ann Lawson; Cathryn S Mah
Journal:  Hum Mol Genet       Date:  2011-04-25       Impact factor: 6.150

5.  Comparison of EQ-5D and SF-6D utilities in Pompe disease.

Authors:  T A Kanters; W K Redekop; M E Kruijshaar; A T van der Ploeg; M P M H Rutten-van Mölken; L Hakkaart
Journal:  Qual Life Res       Date:  2014-10-24       Impact factor: 4.147

6.  Cessation and resuming of alglucosidase alfa in Pompe disease: a retrospective analysis.

Authors:  Thomas Hundsberger; Kai M Rösler; Oliver Findling
Journal:  J Neurol       Date:  2014-06-13       Impact factor: 4.849

7.  Respiratory function in late-onset Pompe disease patients receiving long-term enzyme replacement therapy for more than 48 months.

Authors:  Ilka Schneider; Frank Hanisch; Tobias Müller; Bernd Schmidt; Stephan Zierz
Journal:  Wien Med Wochenschr       Date:  2012-11-19

8.  Enzyme replacement therapy in juvenile glycogenosis type II: a longitudinal study.

Authors:  Laura Deroma; Mattia Guerra; Annalisa Sechi; Giovanni Ciana; Giorgia Cisilino; Andrea Dardis; Bruno Bembi
Journal:  Eur J Pediatr       Date:  2014-01-07       Impact factor: 3.183

9.  Swiss national guideline for reimbursement of enzyme replacement therapy in late-onset Pompe disease.

Authors:  Thomas Hundsberger; Marianne Rohrbach; Lukas Kern; Kai M Rösler
Journal:  J Neurol       Date:  2013-06-08       Impact factor: 4.849

10.  Sleep-Disordered Breathing and Effects of Noninvasive Ventilation in Patients with Late-Onset Pompe Disease.

Authors:  Matthias Boentert; Bianca Dräger; Christian Glatz; Peter Young
Journal:  J Clin Sleep Med       Date:  2016-12-15       Impact factor: 4.062

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.